HomeCompareVMTHF vs PLD

VMTHF vs PLD: Dividend Comparison 2026

VMTHF yields 474.05% · PLD yields 3.18%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VMTHF wins by $40753.60M in total portfolio value
10 years
VMTHF
VMTHF
● Live price
474.05%
Share price
$0.42
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40760.11M
Annual income
$28,806,329,273.60
Full VMTHF calculator →
PLD
PLD
● Live price
3.18%
Share price
$128.78
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.50M
Annual income
$5,256,436.18
Full PLD calculator →

Portfolio growth — VMTHF vs PLD

📍 VMTHF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVMTHFPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VMTHF + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VMTHF pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VMTHF
Annual income on $10K today (after 15% tax)
$40,293.91/yr
After 10yr DRIP, annual income (after tax)
$24,485,379,882.56/yr
PLD
Annual income on $10K today (after 15% tax)
$270.62/yr
After 10yr DRIP, annual income (after tax)
$4,467,970.75/yr
At 15% tax rate, VMTHF beats the other by $24,480,911,911.81/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VMTHF + PLD for your $10,000?

VMTHF: 50%PLD: 50%
100% PLD50/50100% VMTHF
Portfolio after 10yr
$20383.31M
Annual income
$14,405,792,854.89/yr
Blended yield
70.67%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

VMTHF
No analyst data
Altman Z
-0.0
Piotroski
3/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+5.6% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VMTHF buys
0
PLD buys
0
No recent congressional trades found for VMTHF or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVMTHFPLD
Forward yield474.05%3.18%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$40760.11M$6.50M
Annual income after 10y$28,806,329,273.60$5,256,436.18
Total dividends collected$39707.63M$6.37M
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: VMTHF vs PLD ($10,000, DRIP)

YearVMTHF PortfolioVMTHF Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$58,105$47,404.60$11,255$555.24+$46.9KVMTHF
2$319,595$257,422.91$13,062$1,018.59+$306.5KVMTHF
3$1,665,249$1,323,282.78$15,903$1,926.67+$1.65MVMTHF
4$8,225,711$6,443,893.93$20,839$3,823.32+$8.20MVMTHF
5$38,549,580$29,748,069.43$30,464$8,166.08+$38.52MVMTHF
6$171,541,094$130,293,043.94$52,054$19,457.30+$171.49MVMTHF
7$725,407,583$541,858,612.30$109,886$54,188.93+$725.30MVMTHF
8$2,917,676,445$2,141,490,330.46$304,030$186,451.18+$2917.37MVMTHF
9$11,171,756,198$8,049,842,402.84$1,166,125$840,813.32+$11170.59MVMTHF
10$40,760,108,406$28,806,329,273.60$6,504,190$5,256,436.18+$40753.60MVMTHF

VMTHF vs PLD: Complete Analysis 2026

VMTHFStock

Venus Medtech (Hangzhou) Inc. develops and commercializes transcatheter heart valve medical devices in Mainland China and internationally. The company's products include VenusA-Valve, a transcatheter aortic heart valve replacement (TAVR) product to treat severe aortic stenosis; VenusP-Valve is a transcatheter pulmonary valve system to treat the dysfunction of right ventricular outflow tract; V8/TAV8 balloon aortic valvuloplasty catheter systems; and TriGUARD3, a cerebral embolic protection device for minimizing the risk of brain damage and prevent cerebral embolism during TAVR and other structural heart disease surgeries. It also develops VenusA-Plus and VenusA-Pilot, which are TAVR product candidates; and transcatheter mitral and tricuspid valve replacement products; Liwen RF ablation system for the treatment of hypertrophic cardiomyopathy; and renal denervation for the treatment of hypertension. The company was founded in 2009 and is headquartered in Hangzhou, the People's Republic of China.

Full VMTHF Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this VMTHF vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VMTHF vs SCHDVMTHF vs JEPIVMTHF vs OVMTHF vs KOVMTHF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.